Retatrutide

Clinical Summary

Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GIP, GLP-1, and glucagon. It is the first triple agonist to reach Phase 3 clinical trials for obesity. The fatty diacid conjugation extends its half-life to ~6 days, enabling once-weekly subcutaneous dosing.

Who benefits most: Adults with obesity (BMI >=30) or type 2 diabetes with overweight. Phase 2 showed 24.2% mean weight loss at 48 weeks (N=338) and HbA1c -2.02% in T2DM (N=281). Phase 3 has now extended this: TRIUMPH-4 (knee OA, N=445) showed 28.7% weight loss at 68 weeks, and TRANSCEND-T2D-1 (N=537) confirmed HbA1c -2.0% with 16.8% weight loss at 40 weeks.

The honest reality (updated April 2026): Phase 3 results are now emerging. TRIUMPH-4 completed (28.7% weight loss, WOMAC pain -75.8%) and TRANSCEND-T2D-1 completed (HbA1c -2.0%). These confirm Phase 2 efficacy. However, the broader TRIUMPH program (obesity primary endpoint, OSA, CV outcomes) is still ongoing. We lack long-term safety beyond 68 weeks, cardiovascular hard outcomes, and cancer risk data. A massive outcomes trial (TRIUMPH-Outcomes, N=10,000) is underway. Head-to-head trials vs Tirzepatide (TRIUMPH-5, N=800) and vs Semaglutide (TRANSCEND-T2D-2, N=1,250) are active but unreported. Dysesthesia is the key new safety signal: 20.9% at 12 mg in TRIUMPH-4 (higher than the 2.3-4.5% seen in TRANSCEND-T2D-1). This is not a minor footnote — one in five patients at full dose.

What makes it novel: The glucagon receptor component. Unlike Semaglutide (GLP-1 only) or Tirzepatide (GIP + GLP-1), retatrutide adds glucagon agonism which promotes hepatic fat oxidation, increases resting energy expenditure, and may prevent the metabolic adaptation that typically stalls weight loss. The trade-off: glucagon raises blood glucose, but the GLP-1 and GIP components counterbalance this.

Pharma skepticism note: Eli Lilly is investing heavily — 47 registered trials (up from 32 at last count), including a 10,000-patient CV/CKD outcomes study and a novel SYNERGY-Outcomes trial combining retatrutide + tirzepatide for MASH (N=4,500). This is the most ambitious anti-obesity development program ever mounted. First independent trial: Hudson Biotech (not Lilly) is now recruiting a Phase 2 maintenance dose study (NCT07467447, N=300) — the first non-sponsor trial, which partially addresses the single-source bias concern. Safety signals from Phase 2-3 (GI, HR increase, dysesthesia up to 20.9%) are consistent with the incretin class but dysesthesia warrants close attention. Completed Phase 1 PK studies in hepatic impairment (NCT05916560), renal impairment (NCT05611957), and DDIs (metoprolol, oral contraceptives, midazolam/warfarin/caffeine) are building the safety pharmacology database.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Phase 2-3 RCT(s) with strong results | 3/5 Substudy, post-hoc, or unreplicated human data | 2/5 Animal data or trial design only | 1/5 No evidence or speculative

Key Trial Details

Obesity Phase 2 (PMID: 37366315) Jastreboff et al., NEJM 2023. N=338 adults (BMI >=30, no diabetes). Randomized, double-blind, placebo-controlled. 48 weeks. Dose-response across 1, 4, 8, 12 mg. The 12 mg group: mean -24.2% weight loss, 100% hit >=5%, 83% hit >=15%, 26% hit >=30%. Weight loss curve still descending at week 48. Starting at 2 mg (vs 4 mg) during escalation significantly reduced GI side effects.

T2DM Phase 2 (PMID: 37385280) Rosenstock et al., Lancet 2023. N=281 adults with T2DM (~8 yr duration, baseline HbA1c ~8%). Active comparator: Dulaglutide 1.5 mg. Retatrutide 12 mg: HbA1c -2.02% vs -0.01% placebo vs -1.41% dulaglutide. Weight: -16.9% vs -3.0% placebo vs -2.0% dulaglutide. Superior on both endpoints.

MASLD Phase 2a (PMID: 38858523) Sanyal et al., Nature Medicine 2024. Dedicated liver fat substudy. 82-86% achieved normal liver fat at highest doses; 93% of 12 mg group. Dual mechanism: weight loss + glucagon-driven hepatic lipid oxidation.

Body Composition Substudy (PMID: 40609566) Coskun et al., Lancet Diabetes Endocrinol 2025. N=189 from T2DM trial (DXA imaging). Fat mass reduced 23-26% at 8-12 mg. Lean mass relatively preserved vs total weight loss. Visceral fat preferentially reduced. Note: ~25-30% of total weight lost was fat-free mass, consistent with other weight loss interventions at this magnitude.

TRIUMPH-4 Phase 3 — Knee OA (COMPLETED, Dec 2025) N=445. 12 mg dose at 68 weeks: 28.7% body weight loss. WOMAC pain scores reduced 75.8%. Nearly half achieved >=25% weight loss. Met all primary and key secondary endpoints. First Phase 3 result confirming Phase 2 magnitude of effect.

TRANSCEND-T2D-1 Phase 3 (COMPLETED, Mar 2026) N=537. HbA1c reduced 1.7%, 2.0%, 1.9% at 4/9/12 mg vs 0.8% placebo at 40 weeks. Weight loss reached 16.8% (36.6 lb) at 12 mg. New safety signal: dysesthesia in 2.3-4.5% of participants. Discontinuation 2.2-5.1% vs 0% placebo.

TRIUMPH Phase 3 Program (PMID: 41090431) Giblin et al., Diabetes Obes Metab 2026. Design paper for TRIUMPH registration trials covering obesity, obstructive sleep apnea, and knee osteoarthritis. TRIUMPH-4 (knee OA) has reported results. TRIUMPH-3 (obesity + CVD) and master trial ongoing.

TRANSCEND-CKD Phase 2 (PMID: 41160422) Heerspink et al., Nephrol Dial Transplant 2025. N=146 (completed). Design and baseline characteristics published. Results pending.

TRIUMPH-Outcomes (NCT06383390) Massive cardiovascular + CKD outcomes trial. N=10,000. ASCVD + CKD population. Active. Will provide hard CV endpoints (MI, stroke, death).

TRIUMPH-5 — Head-to-Head vs Tirzepatide (NCT06662383) N=800. Phase 3. Active. Results expected December 2026. The comparison the field has been waiting for.

SYNERGY-Outcomes (NCT07165028) Retatrutide + Tirzepatide combination vs placebo for MASH. N=4,500. Phase 3. Recruiting. Novel combination trial.

Prescribing

Dosing

Escalation Protocol (12 mg target, from Phase 2)

• Weeks 1-4: 2 mg once weekly
• Weeks 5-8: 4 mg once weekly
• Weeks 9-12: 6 mg once weekly
• Weeks 13-16: 8 mg once weekly
• Weeks 17-20: 10 mg once weekly
• Week 21+: 12 mg once weekly (maintenance)

Starting at 2 mg (not 4 mg) significantly reduced GI side effects in Phase 2. Slower escalation is better tolerated.

Formulations

This is an investigational drug. Not available outside clinical trials. Not available from compounding pharmacies. Gray-market peptides claiming to be retatrutide are unverified.

Dose-Response Summary

Safety

Interactions

Contraindications

Absolute:

• Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 class black box warning (C-cell tumors in rodents)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy — no safety data; weight loss during pregnancy not recommended
• Hypersensitivity to retatrutide or excipients

Relative:

• Severe gastroparesis — delayed gastric emptying may worsen
• BMI <27 — not studied; risk of excessive weight loss
• History of pancreatitis — GLP-1 class concern
• Severe renal impairment (eGFR <30) — limited safety data
• Active gallbladder disease — rapid weight loss increases cholecystitis risk
• Severe depression/suicidal ideation — monitor (unclear causal relationship, regulatory caution)

Adverse Effects

Common (>10%):

Common-to-Uncommon (variable by trial): abdominal pain, decreased appetite (desired but sometimes excessive), fatigue, dizziness, increased heart rate (+5-10 bpm, persistent throughout treatment — not just titration-phase; reverses on discontinuation), injection site reactions, cutaneous hyperesthesia (7%, mild), dysesthesia (20.9% at 12 mg in TRIUMPH-4; 2.3-4.5% in TRANSCEND-T2D-1 — the discrepancy may reflect population differences, dose, or duration. This is the most significant new safety signal — tingling, numbness, altered sensation. Linked to glucagon receptor activity. One in five patients at full dose in the larger, longer trial).

Rare (<1%): acute pancreatitis (1 case in Phase 2), gallbladder disease (theoretical with rapid weight loss), elevated ALT >3x ULN (~1%, transient).

Class-level safety data: Meta-analysis of GLP-1 RAs (PMID: 40988099, 62 RCTs, N=66,232) showed slightly increased pancreatitis risk (RR 1.44, 95% CI 1.09-1.89) but not significant when stratified by background medications. No significant pancreatic cancer association (RR 1.30, 95% CI 0.86-1.97).

Discontinuation rate: Phase 2 obesity: 6-16% (vs 0% placebo). Phase 3 TRANSCEND-T2D-1: 2.2-5.1% (vs 0% placebo). Lower Phase 3 rates suggest optimized titration protocols help.

Heart rate: Mean increase of 5-10 bpm, peaking at 24 weeks then declining. One case of QT prolongation occurred on concomitant ondansetron (drug interaction, not intrinsic). Cardiac contractile effects studied in isolated mouse and human atrial tissue — inotropic effects observed (PMIDs: 40464942, 40613938) — clinical significance unclear. Meta-analysis of GLP-1 RA HR effects (PMID: 41582189) contextualizes this within the incretin class.

FAERS Signal Table (from BioMCP)

Reading FAERS data: Only 14 total FAERS reports exist for retatrutide — extremely thin for any compound, consistent with pre-approval status. ~5 of 14 reports involve product misuse, counterfeit product, dispensing errors, or advertising issues (gray-market access). New since last review: chest pain/dyspnoea (1 life-threatening report, 29F), peripheral neuropathy and burning sensation (may presage the Phase 3 dysesthesia signal), muscle atrophy (1 report — consistent with lean mass loss at this weight loss magnitude). No novel safety signals beyond known incretin class effects and the emerging dysesthesia pattern. All reports date from 2024+ (pre-approval off-label/gray-market use).

Monitoring

Baseline: weight, BMI, waist circumference, BP, heart rate, HbA1c, fasting glucose, CMP (renal/hepatic), lipid panel, TSH if thyroid history, pregnancy test if applicable.

During treatment:

Synergies & Stacking

NOT recommended combinations:

• Retatrutide + Semaglutide or Tirzepatide: overlapping mechanisms, likely additive toxicity with uncertain benefit. Exception: SYNERGY-Outcomes (NCT07165028) is now testing retatrutide + tirzepatide combination for MASH (N=4,500) — Lilly is exploring whether the combo has synergistic liver benefits.
• Retatrutide + other GLP-1 RAs: redundant; increased GI side effects.

Individual Response Modifiers

Reading this section: Only modifiers with evidence for THIS specific compound are listed. Retatrutide is still investigational with limited pharmacogenomic data. Most sex-specific differences are inferred from the incretin class rather than retatrutide-specific studies.

Sex-Specific Considerations

Genetic Modifiers

No known pharmacogenomic modifiers specific to retatrutide. The compound is degraded proteolytically (not via CYP enzymes), making standard CYP2D6/CYP3A4 polymorphisms less relevant than for small-molecule drugs. Potentially relevant class-level variants:

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Strongly Positive / Hyped across ~10,000-20,000 active discussants. Called "Godzilla of weight loss" on Reddit. Approaches irrational exuberance in some communities. High gray-market purchasing activity despite investigational status. Mainstream media now covering the practice (NYT feature on biohacker "Clavicular" sourcing raw retatrutide powder from China; WBUR March 2026 investigative report on unregulated injectables).

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No structured MLM detected. Hype driven by genuine user enthusiasm + unregulated vendor marketing.
• Influencer concentration: TikTok before/after content with discount codes to unregulated vendors. Telegram groups with injection tutorials. Referral-code marketing pattern detected. NYT-featured biohacker "Clavicular" sourcing raw powder from China — mainstream media amplification of gray-market use.
• Astroturfing signals: Some suspiciously similar product reviews on peptide vendor sites. "GLP-3" misnomer spreading indicates sources lacking pharmacological understanding. 34% of Certificates of Analysis (COAs) in 2025 were photoshopped (Finnrick Analytics).
• Commercial bias: Gray-market vendors ($50-70/mo research vendors, $150/6mo Chinese factories, compounding pharmacies $200-500/mo) have strong financial incentive to promote. FDA issued 30+ warning letters in March 2026 targeting compounded GLP-1 products. New pattern: telehealth/med spa sites publishing SEO-optimized retatrutide content as lead generation — PURE Medical Spa, Better Med Spa, NDA Medical Spa examples.
• Supply chain danger: Reports of vials containing salt water or insulin sold as "retatrutide." No quality assurance for gray-market supply. Finnrick Analytics now publishes vendor safety testing/ratings as third-party verification resource.
• WBUR investigative report (March 2026): Mainstream media now covering unregulated injectable peptides from Chinese factories — public awareness increasing.

Folk vs Clinical Reality Check

Community weight loss reports largely align with Phase 2-3 clinical data (24-29%). Food noise elimination is the most striking subjective report and is supported by Phase 2 PRO data (PMID: 40916752). Sex difference aligns with clinical data: women lose more weight (28.5% vs 21.2% in Phase 2), confirmed in community reports. Dysesthesia aligns: the LessWrong "electric tickling from clothing" N=1 report maps directly to TRIUMPH-4's 20.9% dysesthesia rate — community and clinical data converge here. The key divergences: (1) community uses unverified supply with zero quality control (34% of COAs forged), (2) community skips safety monitoring entirely, (3) community stacking — especially the Reta+Tirz "Super Stack" — has zero evidence base and may be genuinely dangerous, (4) the MASLD/liver fat benefit is undersold in communities relative to its clinical significance, (5) mental health effects are undermonitored — one ExcelMale user reported intolerable anxiety at any dose, and the GLP-1 class has mixed data (one pharmacovigilance study shows 195% higher risk of major depression, but a meta-analysis shows GLP-1 therapy improves depression scores), and (6) non-responders exist but are rarely discussed (survivorship bias in community reports).

Deep Dive: Mechanisms & Research

Triple Agonism Rationale

Retatrutide is a single peptide chain conjugated to a fatty diacid moiety. Receptor potency relative to native ligands:

• GIP receptor: 8.9x MORE potent than native GIP
• GLP-1 receptor: 0.4x potency vs native GLP-1 (less potent)
• Glucagon receptor: 0.3x potency vs native glucagon (less potent)

Source: Coskun et al., Cell Metab 2022 (PMID: 35952664) — preclinical characterization and Phase 1b proof of concept in 72 T2DM patients.

GIP receptor agonism: Enhances glucose-dependent insulin secretion. Paradoxically improves insulin sensitivity when combined with GLP-1/glucagon activity despite GIP's role in fat storage. May positively influence bone turnover.

GLP-1 receptor agonism: Appetite suppression via hypothalamic/brainstem satiety centers. Delays gastric emptying. Glucose-dependent insulin release (low hypo risk). Cardiovascular benefits (BP reduction, lipid improvement). Beta cell preservation.

Glucagon receptor agonism — the differentiator: Increases resting energy expenditure and hepatic fat oxidation. Promotes lipolysis and thermogenesis. Contributes to LDL-C reduction (~20%) likely via PCSK9 degradation. This component prevents the metabolic adaptation ("metabolic slowdown") that stalls weight loss with GLP-1-only agents. The trade-off (hyperglycemic tendency) is counterbalanced by GIP + GLP-1 insulin effects.

Synergistic logic:

• GLP-1 + Glucagon = appetite suppression + increased energy expenditure = enhanced net weight loss
• GIP + GLP-1 = synergistic insulin secretion + beta cell protection
• GIP + Glucagon = metabolic flexibility + hypoglycemia prevention
• Triple = maximum weight loss with preserved lean mass and metabolic health

Pharmacokinetics

• Half-life: ~6 days (once-weekly dosing)
• Absorption: SubQ, dose-proportional
• Steady state: ~4-5 weeks of weekly dosing
• Distribution: Fatty acid conjugation creates slow-release subcutaneous depot
• Metabolism: Presumed proteolytic degradation (not extensively characterized)
• Gastric emptying: Significantly delayed (PMID: 37208899, Urva et al. 2023)

Comparator Landscape

Retatrutide's 28.7% weight loss at 68 weeks (Phase 3 TRIUMPH-4) is the largest reported for any anti-obesity medication. Cross-trial comparisons remain unreliable. Head-to-head data is coming: TRIUMPH-5 (NCT06662383, retatrutide vs tirzepatide, N=800, results expected Dec 2026) and TRANSCEND-T2D-2 (NCT06260722, retatrutide vs semaglutide, N=1,250, completion Jan 2027).

Indirect comparison from Bayesian NMA (PMID: 40685589): retatrutide -16.34 kg vs tirzepatide -11.82 kg; percentage -23.77% vs -16.79%. However, retatrutide had higher AE frequency (RR 4.10 vs 2.78).

Recent Research (2024-2026)

Network Meta-Analyses (2024-2026):

• Xie et al. (PMID: 39305981, Metabolism 2024): NMA of 7 GLP-1 RAs and polyagonists. Retatrutide 12 mg (-22.1%) and 8 mg (-20.7%) ranked among the three most efficacious for weight loss.
• Sinha & Ghosal (PMID: 40685589, Obesity 2025): Bayesian NMA confirming retatrutide's position as top-ranked weight loss agent.
• Abulehia et al. (PMID: 41787737, Endocrinol Diabetes Metab 2026): NMA of glucagon receptor agonists on metabolic outcomes. Comparative efficacy across the class.
• Chan et al. (PMID: 41711462, Cardiol Rev 2026): Systematic review of dual and triple agonists in overweight/obese — meta-analytic confirmation of class efficacy.
• Pasqualotto et al. (PMID: 39318607, Metabol Open 2024): Systematic review and meta-analysis confirming dose-dependent efficacy and GI adverse event profile.

Mechanistic & Preclinical (2025-2026):

• Li et al. (PMID: 41964043, Diabetol Metab Syndr 2026): Multi-omic profiling showing retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair — potential mechanism for sustained metabolic benefit.
• Briand et al. (PMID: 41741376, Obesity 2026): Diet-induced obese MASH mouse and hamster models showing multiple metabolic benefits of retatrutide — supports MASLD/MASH indication.
• Viebahn et al. (PMID: 41056349, Am J Physiol 2025): Retatrutide improves steatohepatitis in accelerated mouse MASH model with fructose binge.
• Hitaka et al. (PMID: 41723268, Int J Obes 2026): Efficacy comparison of semaglutide, tirzepatide, and retatrutide in MC4R-deficient obesity models — relevant for genetic obesity.

Cardiac Effects:

• Neumann et al. (PMID: 40464942, 2025; PMID: 40613938, 2026): Contractile/inotropic effects of retatrutide in isolated mouse and human atrial preparations. Clinical significance uncertain but warranting monitoring.

Behavioral & Patient-Reported:

• Kanu et al. (PMID: 40916752, Diabetes Obes Metab 2025): Appetite, eating attitudes, and eating behaviors during retatrutide in T2DM Phase 2. Quantifies the behavioral changes driving weight loss.
• Kanu et al. (PMID: 40735804, Diabetes Obes Metab 2025): Association between patient-reported eating behaviors and weight change — secondary analysis.
• Goetz et al. (PMID: 41216380, Obes Pillars 2025): Qualitative study of perceived benefits in Phase 2 participants.

Cancer (Preclinical):

• Cui et al. (PMID: 39868848, Adv Sci 2025): Retatrutide inhibits HBP/YAP O-GlcNAcylation pathway in obese TNBC mouse models. Reduces tumor size and enhances chemotherapy efficacy in obese mice bearing TNBC tumors. Mechanism: adipocyte-mediated metabolic reprogramming → HBP upregulation → YAP stabilization → tumor growth. Retatrutide disrupts this axis. Preclinical only — no human data. First evidence of anti-tumor potential for any triple agonist.

CKD:

• Pallavi et al. (PMID: 41537067, Maedica 2025): Systematic review and meta-analysis of retatrutide in diabetes/obesity comorbid with CKD. Safety and efficacy signal in renal population.

Heart Rate Meta-Analysis:

• Zhang et al. (PMID: 41582189, Eur J Med Res 2026): Heart rate effects of GLP-1 RAs in non-diabetic overweight/obesity — contextualizes retatrutide's HR increase within the class.

Pancreatitis/Pancreatic Cancer (Class-Level):

• Wen et al. (PMID: 40988099, Endocrinol Diabetes Metab 2025): Meta-analysis of 62 RCTs (N=66,232). GLP-1 RAs: pancreatitis RR 1.44 (95% CI 1.09-1.89) — not significant when stratified by background meds. Pancreatic cancer: no significant association (RR 1.30, 95% CI 0.86-1.97).

Kidney Outcomes (Phase 2 Analysis):

• Heerspink et al. (PMID: 40630318, Kidney Int Rep 2025): First dedicated renal parameter analysis from Phase 2 — showing kidney parameter improvements with retatrutide.

Lipid Mechanism:

• Wen et al. (PMID: 40726454, Diabetes Obes Metab 2025): ANGPTL3/8 protein reductions during retatrutide treatment parallel serum lipid reductions — explains the ~20% LDL-C lowering via angiopoietin-like protein pathway.

Alcohol/Addiction (Preclinical):

• Windram et al. (PMID: 40699363, Psychopharmacology 2025): Retatrutide (alongside semaglutide and tirzepatide) attenuates interoceptive effects of alcohol in male and female rats — novel addiction domain crossover.

Structural Biology:

• Li et al. (PMID: 39019866, Cell Discov 2024): Cryo-EM structural insights into retatrutide's triple agonism — how one peptide simultaneously binds GLP-1R, GIPR, and GCGR.

Obesity-Associated Cancer (Preclinical):

• Marathe et al. (PMID: 40094000, NPJ Metab Health Dis 2025): Retatrutide alleviates obesity-associated cancer progression in preclinical models — broader cancer application beyond the TNBC finding.

Diabetic Kidney Disease (Preclinical Comparison):

• Ma et al. (PMID: 39212900, Endocrine 2025): Head-to-head preclinical comparison of liraglutide, tirzepatide, and retatrutide in diabetic kidney disease db/db mouse model.

Sex Differences (Class-Level + Retatrutide-Specific):

• Yang et al. (PMID: 40040445, J Diabetes 2025): Systematic review and meta-analysis of sex differences in GLP-1 RA efficacy for weight reduction — found sex-dependent differences across the class.
• Misra et al. (PMID: 40728138, J Basic Clin Physiol Pharmacol 2025): Systematic review of retatrutide clinical trials — confirmed women showed higher proportional weight loss (28.5% vs 21.2% in Phase 2).

PCOS (Emerging Indication):

• Hudanich et al. (PMID: 41141001, Cureus 2025): Scoping review of GLP-1 RA effects on PCOS. Mentions retatrutide as potential future therapy via weight loss, insulin sensitization, and androgen reduction. No direct retatrutide-PCOS data.

Psychiatric / Addiction (Class-Level Signals):

• Himmerich H (PMID: 40042613, Nervenarzt 2025): Reviews whether GLP-1 RAs could be psychiatric treatments — appetite/reward pathway modulation relevant to binge eating disorder and potentially depression.
• Himmerich et al. (PMID: 39096466, CNS Drugs 2024): Pharmacological treatment of binge eating disorder — positions GLP-1 RA class including retatrutide as potential BED treatments.

Blood Pressure (Meta-Analysis):

• Basile et al. (PMID: 40899050, Eur J Prev Cardiol 2025): Systematic review and meta-analysis of incretin therapies on blood pressure — retatrutide associated with systolic BP reductions of 4-7 mmHg at higher doses.

Cardiovascular Events (Non-Diabetic):

• Yin et al. (PMID: 40207414, J Diabetes 2025): Chinese meta-analysis of GLP-1 RA-based therapies on cardiovascular events in obese non-diabetic individuals — retatrutide data shows favorable cardiometabolic parameter changes.

Drug Design (Triple Agonist Benchmarking):

• Wang et al. (PMID: 40958513, J Med Chem 2025): Chinese group designed novel triple agonists using retatrutide as benchmark — demonstrated different receptor potency ratios can achieve comparable effects, informing next-gen drug design.

Supply Chain / Policy:

• DiStefano et al. (PMID: 39776466, J Pharm Policy Pract 2025): Documents compounded GLP-1 RA direct-to-consumer market in Colorado — retatrutide already appearing in gray-market compounding offerings despite not being FDA-approved.

Liver (MASLD/MASH Reviews):

• Malandris et al. (PMID: 41831086, Curr Diab Rep 2026): Positions retatrutide as having strongest MASH signal among incretins (up to 90% liver fat reduction).
• Wang et al. (PMID: 40489581, J Clin Endocrinol Metab 2025): Systematic review and meta-analysis of GLP-1 therapies on MASLD/MASH.

GI Adverse Effects (Class-Level):

• Takrori et al. (PMID: 41303824, Medicina 2025): Systematic review of GI adverse effects across anti-obesity medications in non-diabetic adults. Retatrutide had notable GI profile consistent with GLP-1 RA class.

Fat-Free Mass Impact of Weight Loss:

• Stefanakis et al. (PMID: 39481534, Metabolism 2024): Review warning >25% of weight lost from GLP-1 RA therapy is typically fat-free mass. Discusses myostatin-activin-follistatin system and potential combination with body composition agents (bimagrumab, trevogrumab).

Patient-Reported Outcomes:

• Kanu et al. (PMID: 41589220, Obes Sci Pract 2026): Development of Weight and Emotions Scale (WES) — 16-item PRO measure developed from retatrutide Phase 2 trial exit interviews (N=40). Captures emotional functioning impact of obesity treatment.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total registered trials: 47 (17 Phase 3, 4 Phase 2, 22 Phase 1, 4 other). This is the most extensive anti-obesity development program ever mounted. First non-Lilly trial: Hudson Biotech (NCT07467447) is recruiting a maintenance dose study — a milestone for independent investigation.

Regulatory Status (from BioMCP)

• FDA: Not approved. Investigational. NDA expected Q4 2026 or Q1 2027. PDUFA target mid-late 2027.
• EMA: Not approved. No marketing authorization application filed.
• PMDA (Japan): Not approved. Phase 1 in Japanese participants completed (NCT04823208).
• NMPA (China): Not approved. Phase 1 in Chinese participants completed (NCT05548231).
• MFDS (Korea): No registry entries found. No CRiS registrations.
• East Asian registries (JPRN, CRiS, ChiCTR): No retatrutide-specific registrations identified outside ClinicalTrials.gov.
• Regulatory context: Retatrutide is a well-funded Eli Lilly asset with an active, advancing clinical program. "Not approved" status reflects standard regulatory timeline for a Phase 3 compound, not safety or efficacy concerns. Commercial viability is high given the $50B+ GLP-1 RA market. The dysesthesia signal (20.9% at 12 mg in TRIUMPH-4) will require careful FDA review — characterization of mechanism and reversibility will be key for labeling.

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale for each classification below.

Hype Check (Mode 1: Fallacy Radar)

• Appeal to novelty (MEDIUM): "Triple is better than dual which is better than single" — plausible mechanism but not guaranteed. More receptor targets = more effects to monitor, not inherently better. Glucagon agonism carries real risks: dysesthesia in 20.9% at 12 mg (TRIUMPH-4) is a novel signal not seen with dual or single agonists.
• Survivorship bias (LOW→MEDIUM): Phase 3 is confirming Phase 2 — the compound IS delivering. But the full TRIUMPH program is incomplete. The remaining "if" is long-term safety and CV outcomes.
• Cherry-picking risk (LOW): The 28.7% figure is the 12 mg group at 68 weeks in the TRIUMPH-4 (knee OA) population. The 1 mg group lost only 8.7% in Phase 2. Dose-dependent framing is honest, but headlines cherry-pick the maximum.
• Meta-analysis recycling (MEDIUM): New flag. 12+ meta-analyses/NMAs now exist for retatrutide, but ALL draw from the same 2-3 Lilly-sponsored Phase 2 trials. More meta-analyses ≠ more independent evidence. It's the same data re-analyzed with different statistical methods. This creates a false appearance of massive independent replication.
• Argument from progress (LOW): TRIUMPH-4 at 68 weeks shows continued efficacy but we still lack plateau data.
• UPDATE (April 2026): Phase 3 results (TRIUMPH-4, TRANSCEND-T2D-1) have reduced the survivorship bias concern. First non-Lilly trial (Hudson Biotech) partially addresses single-source concern. Dysesthesia at 20.9% is a genuine new risk to weigh.

Evidence Gaps

• No Phase 3 primary obesity endpoint yet — TRIUMPH-4 was knee OA (obesity secondary). The obesity-primary TRIUMPH-3 is ongoing.
• No data >68 weeks — long-term safety, weight trajectory plateau, bone density effects all unknown.
• No CV hard outcomes — TRIUMPH-Outcomes (N=10,000) will address MI, stroke, cardiovascular death. Semaglutide and tirzepatide have CV outcomes data; retatrutide does not.
• No head-to-head results — TRIUMPH-5 (vs tirzepatide) and TRANSCEND-T2D-2 (vs semaglutide) are active but unreported.
• No weight maintenance data — NCT06859268 (N=643) is active. Can a lower maintenance dose preserve loss?
• No bone density data — critical gap at 28.7% weight loss. Postmenopausal women at particular risk.
• No pharmacogenomic data — who are the exceptional (>=30% loss) and poor responders?
• No systematic mental health assessment — FDA has flagged the GLP-1 class. Dysesthesia (2.3-4.5%) in Phase 3 is a new neurological signal.
• Cancer risk unknown — the TNBC preclinical finding (PMID: 39868848) is intriguing but no human data. Long-term cancer surveillance needed.

Bias Flags (Mode 4: First Principles)

• Single-source funding (partially addressed): All major trials WERE Eli Lilly-funded. Hudson Biotech now recruiting a Phase 2 maintenance dose study (NCT07467447, N=300) — the first independent trial. However, all existing Phase 3 data is still Lilly-sponsored. 12 of 12 meta-analyses use the same 2-3 Lilly trials as source data. Independent post-marketing surveillance will be critical.
• Publication timing: Phase 2 results were released with orchestrated media coverage at major conferences. Phase 3 topline results (TRIUMPH-4, TRANSCEND-T2D-1) were press-released before full peer review. This is normal pharma practice but shapes narrative before independent scrutiny.
• Comparator selection: Phase 2 T2DM trial used Dulaglutide 1.5 mg (an older, less potent GLP-1 RA) as active comparator — making retatrutide look better. Head-to-head vs Tirzepatide or Semaglutide at optimal doses would be the real test.
• Population generalizability: Phase 2 populations were relatively healthy obese adults and T2DM patients. Real-world populations will be more complex (polypharmacy, comorbidities, lower adherence).

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Triple agonist" branding positions retatrutide as "next generation" — marketing language embedded in scientific framing. Weight loss percentages (24-29%) consistently highlighted over absolute weight change. "Approaching bariatric surgery results" is emotionally charged framing. New pattern: 12+ meta-analyses from independent teams create an illusion of broad scientific consensus, but all analyze the same Lilly trial data.
• Influencer economics: No significant KOL influencer ecosystem yet for the compound itself, but several obesity medicine KOLs serve on Lilly advisory boards (disclosed). Gray-market vendors have built influencer networks on TikTok/Telegram for unregulated sales. New pattern: telehealth/med spa sites (PURE Medical Spa, Better Med Spa, NDA Medical Spa) publishing SEO-optimized "educational" content as patient lead generation for off-label prescribing.
• Counter-narrative manipulation: Novo Nordisk (semaglutide) and BI (survodutide) have competitive incentive to emphasize retatrutide's GI side effects and glucagon risks. The dysesthesia signal (20.9%) could be weaponized by competitors. FDA's GLP-1 class safety communication (suicidal ideation, thyroid) applies broadly and could be weaponized by either direction.
• Cui bono summary: Eli Lilly wins enormously if retatrutide succeeds ($50B+ GLP-1 market). Patients with obesity genuinely benefit. Competitors (Novo Nordisk) and bariatric surgeons lose market share. Gray-market vendors profit from pre-approval hype (34% of COAs forged). Anti-pharma advocates have ideological incentive to dismiss. New actor: Hudson Biotech entering with independent trial — potentially a future competitor or licensing partner.
• Red team highlight: The single most concerning angle is historical precedent — rimonabant (CB1 antagonist) showed impressive Phase 2 weight loss and was pulled for psychiatric AEs in Phase 3/post-marketing. Sibutramine was pulled for CV events. The dysesthesia signal at 20.9% (TRIUMPH-4) is the closest retatrutide has come to a potential class-differentiating safety issue. If this proves to be persistent or progressive neuropathy rather than transient tingling, it could derail approval. TRIUMPH-Outcomes (N=10,000) is the necessary safeguard.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 for appropriate indications (obesity BMI >30, T2DM, MASLD) — triple agonist (GLP-1/GIP/glucagon) with best-in-class Phase 3 weight-loss and metabolic data; investigational status, injectable format, and narrow indication (obesity/T2DM) cap general-population utility, but utility is very high for people with the target indications.
• Opportunity cost: Adding an investigational injectable requires weekly injections, blood monitoring, and navigating either clinical trial enrollment or gray-market supply (not recommended). Time, financial, and complexity costs are high relative to current supplement-based approach.
• Verdict: WATCH LIST — Genuinely exciting compound worth tracking closely. Revisit when: (1) TRIUMPH-5 head-to-head vs tirzepatide results publish (expected Dec 2026), (2) TRIUMPH-Outcomes CV data becomes available, (3) FDA approval and commercial availability. Not actionable for non-indicated users outside a clinical trial.
• Conditions for upgrade to ADD: BMI >30 or T2DM diagnosis, OR FDA approval with favorable long-term safety profile, OR MASLD diagnosis with elevated liver enzymes unresponsive to lifestyle intervention.

Bottom Line

Retatrutide is the most potent anti-obesity compound in clinical development. Phase 3 results (28.7% weight loss at 68 weeks in TRIUMPH-4, HbA1c -2.0% in TRANSCEND-T2D-1) confirm Phase 2 efficacy — the compound is delivering on its promise. The 47-trial development program (up from 32) including a 10,000-patient CV outcomes study, head-to-head trials vs tirzepatide and semaglutide, a novel combination trial with tirzepatide for MASH, and the first independent trial (Hudson Biotech) reflects both Lilly's conviction and broader industry interest. The dysesthesia signal (20.9% at 12 mg in TRIUMPH-4) is the most significant new concern — if this proves to be progressive neuropathy rather than transient tingling, it could delay or complicate approval. The remaining unknowns are long-term safety (>68 weeks), cardiovascular hard outcomes, bone density effects, and characterization of the dysesthesia mechanism. NDA expected Q4 2026–Q1 2027, PDUFA target mid-late 2027. For biohackers without obesity, this is a WATCH LIST compound — fascinating to follow, premature to use.

Practical Notes

• Not available for purchase. Retatrutide is only accessible through clinical trial enrollment or (not recommended) gray-market sources. FDA issued 30+ warning letters in March 2026 targeting compounded GLP-1 products. Retatrutide cannot be legally compounded — fails all 3 criteria for 503A/503B compounding (no USP/NF monograph, not an approved drug component, not on shortage list). The Alliance for Pharmacy Compounding (A4PC) explicitly warned members NOT to compound. Gray-market vials are unverified — 34% of COAs in 2025 were photoshopped (Finnrick Analytics). Reports of salt water and insulin sold as "retatrutide." Research vendor pricing has dropped to ~$50-70/mo.
• If you're in a trial: slow dose escalation (start 2 mg, not 4 mg) significantly reduces GI side effects. Eat smaller, blander meals during escalation. Stay hydrated. Report any tingling/numbness immediately — dysesthesia occurred in 20.9% at 12 mg (TRIUMPH-4). This is the most significant new safety signal and may be linked to glucagon receptor activity. Mechanism and reversibility are being characterized.
• Weight regain after stopping is expected — this is a chronic disease requiring chronic therapy, same as statins for cholesterol. Weight maintenance trial (NCT06859268) is testing lower maintenance doses.
• Lean mass preservation: ~25-30% of weight lost is from fat-free mass (similar to other interventions at this magnitude). Resistance training + adequate protein (1.2-1.6 g/kg/day) is non-negotiable. Body composition agents (bimagrumab) are in development for adjunctive use.
• Drug interaction management: if diabetic on insulin or sulfonylureas, proactively reduce those doses 20-50% when starting retatrutide to avoid hypoglycemia.
• Comparison shopping: if you have access to approved alternatives, Tirzepatide (Zepbound) or Semaglutide (Wegovy) are FDA-approved with proven long-term data including cardiovascular outcomes. Retatrutide may prove superior (head-to-head data expected Dec 2026), but it is not yet proven or approved.
• Nausea management pearl: prophylactic antiemetics are NOT recommended per trial investigators — dietary modification and slow escalation are more effective. Community reports 3-4 AM wake-ups during titration — may be related to nocturnal mild hypoglycemia; bedtime protein snack may help.
• Fatigue pattern: unique to triple agonists — the glucagon component forces higher energy expenditure while intake is suppressed ("double deficit"). Peaks weeks 4-10, resolves by month 3-4 for most users. Not a reason to stop; adaptation occurs.

What We Don't Know

• Primary obesity endpoint Phase 3: TRIUMPH-4 (knee OA) confirmed efficacy; TRIUMPH-3 (primary obesity indication) still ongoing
• Long-term safety (>68 weeks): cardiovascular hard outcomes (MI, stroke, death), cancer risk, pancreatitis incidence — TRIUMPH-Outcomes (N=10,000) will answer
• Weight loss plateau: TRIUMPH-4 showed 28.7% at 68 weeks; where does it stabilize? Does loss continue beyond 72 weeks?
• Weight maintenance dosing: can 4-8 mg preserve loss achieved with 12 mg? (NCT06859268 is testing this)
• Head-to-head vs Tirzepatide: TRIUMPH-5 results expected December 2026; the most anticipated comparison in obesity medicine
• Bone density: 28.7% weight loss is concerning for bone mineral density — no DXA bone data published for retatrutide
• Muscle function: lean mass "relatively preserved" by DXA quantity, but functional measures (strength, physical performance) not assessed
• Dysesthesia mechanism: new signal (2.3-4.5%) in TRANSCEND-T2D-1 — cause unclear, needs characterization
• Mental health effects: no systematic assessment; FDA flagged for GLP-1 class. Community reports of anxiety exist.
• Effects after GLP-1 RA failure: does retatrutide work in patients who failed semaglutide or tirzepatide? The glucagon component suggests it might, but zero data
• Genetic obesity in humans: preclinical MC4R data (PMID: 41723268) but no human pharmacogenomic data
• MASH combination therapy: SYNERGY-Outcomes (retatrutide + tirzepatide) is a novel concept — no precedent for combining two incretin-based therapies
• Dysesthesia mechanism: 20.9% at 12 mg (TRIUMPH-4) vs 2.3-4.5% (TRANSCEND-T2D-1) — is it dose-dependent, duration-dependent, population-dependent, or a reporting artifact? Is it reversible? Is it progressive? Glucagon receptor-mediated neuropathy vs transient tingling changes the risk calculus dramatically
• PCOS as potential indication: Scoping review (PMID: 41141001) identifies GLP-1 RA class as potentially beneficial for PCOS via weight loss + insulin sensitization + androgen reduction — no retatrutide-specific data
• Binge eating disorder: GLP-1 class appetite/reward modulation relevant (PMID: 39096466, 40042613) — no retatrutide-specific data
• Cost and access: pricing, insurance coverage, real-world availability — all unknown until approval (NDA expected Q4 2026–Q1 2027, PDUFA target mid-late 2027)

References

Primary Clinical Trials

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet 2023;402(10401):529-544. PMID: 37385280. DOI: 10.1016/S0140-6736(23)01053-X
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med 2024;30(7):2037-2048. PMID: 38858523. DOI: 10.1038/s41591-024-03018-2
4. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes. Lancet Diabetes Endocrinol 2025;13(8):674-684. PMID: 40609566. DOI: 10.1016/S2213-8587(25)00092-0

Phase 3 Trial Designs & Results

5. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab 2026. PMID: 41090431
6. Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial. Nephrol Dial Transplant 2025. PMID: 41160422

Systematic Reviews & Meta-Analyses

7. Xie Z, Zheng G, Liang Z, et al. Seven GLP-1 receptor agonists and polyagonists for weight loss: NMA. Metabolism 2024;161:156038. PMID: 39305981
8. Pasqualotto E, Ferreira ROM, Chavez MP, et al. Effects of once-weekly subcutaneous retatrutide: systematic review and meta-analysis. Metabol Open 2024;24:100321. PMID: 39318607
9. Sinha B, Ghosal S. Efficacy and Safety of GLP-1 RAs, Dual Agonists, and Retatrutide for Weight Loss: Bayesian NMA. Obesity 2025. PMID: 40685589
10. Abulehia A, Ayesh H, Ayesh O, et al. Glucagon Receptor Agonists on Metabolic Outcomes: NMA. Endocrinol Diabetes Metab 2026. PMID: 41787737
11. Chan ZH, Omar AS, Gill K, et al. Incretin-Based Dual and Triple Agonists: Systematic Review and Meta-Analysis. Cardiol Rev 2026. PMID: 41711462
12. Pallavi K, Chandra A, Kumar K, et al. Retatrutide in Diabetes/Obesity Comorbid with CKD: Systematic Review and Meta-Analysis. Maedica 2025. PMID: 41537067
13. Yan K, Yu H, Blaise B. Beyond GLP-1: dual and triple incretin agonists in T2DM: NMA. Acta Diabetol 2025;62(9):1359-1370. PMID: 40471293
14. Guo H, Yang J, Huang J, et al. Comparative efficacy and safety of GLP-1 RAs for weight reduction: model-based meta-analysis. Obes Pillars 2025;13:100162. PMID: 39980735
15. Wen J, Nadora D, Bernstein E, et al. Pancreatitis and Pancreatic Cancer Among GLP-1 RAs: Meta-Analysis of 62 RCTs. Endocrinol Diabetes Metab 2025;8(5):e70113. PMID: 40988099

Mechanistic & Preclinical

16. Coskun T, Sloop KW, Loghin C, et al. LY3437943: from discovery to clinical proof of concept. Cell Metab 2022;34(9):1234-1247.e9. PMID: 35952664
17. Urva S, O'Farrell L, Du Y, et al. Retatrutide delays gastric emptying. Diabetes Obes Metab 2023;25(9):2784-2789. PMID: 37208899
18. Li Q, Cheng W, Zhang J, et al. Multi-omic profiling: Retatrutide alleviates adipose tissue fibrosis. Diabetol Metab Syndr 2026. PMID: 41964043
19. Briand F, Le Cudennec C, Grasset E, et al. Retatrutide in MASH Mouse and Hamster Models. Obesity 2026. PMID: 41741376
20. Viebahn GK, Khurana A, Freund L, et al. Retatrutide improves steatohepatitis in mouse MASH model. Am J Physiol 2025. PMID: 41056349
21. Hitaka K, Sugawara T, Matsumoto M, et al. GLP-1 analogs on MC4R deficient obesity. Int J Obes 2026. PMID: 41723268
22. Neumann J, et al. Contractile effects in isolated mouse atrial preparations. Naunyn Schmiedebergs Arch Pharmacol 2025. PMID: 40464942
23. Neumann J, et al. Inotropic effects in isolated human atrial preparations. Naunyn Schmiedebergs Arch Pharmacol 2026. PMID: 40613938
24. Cui X, Zhu Y, Zeng L, et al. Retatrutide overcomes therapeutic barrier of obese TNBC via HBP/YAP axis. Adv Sci 2025;12(11):e2407494. PMID: 39868848

Reviews & Secondary Sources

25. Drucker DJ. Efficacy and Safety of GLP-1 Medicines. Diabetes Care 2024;47(11):1873-1888. PMID: 38843460
26. Tetelbaun L, Mullally JA, Frishman WH. The First Triple Agonist for Antiobesity. Cardiol Rev 2024. PMID: 39724554
27. Panou T, Gouveri E, Popovic DS, et al. Retatrutide in T2DM and obesity: an overview. Expert Rev Clin Pharmacol 2026. PMID: 41785010
28. Ganamurali N, Sabarathinam S. The Triple-Agonist Revolution. Clin Pharmacol Drug Dev 2026. PMID: 41545327
29. Son JW, le Roux CW, Bluher M, et al. Novel GLP-1-based Medications. Endocr Rev 2026. PMID: 41054801
30. Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: multi-receptor agonists. Metabol Open 2026;30:100463. PMID: 41948476
31. Stefanakis K, Kokkorakis M, Mantzoros CS. Weight loss impact on fat-free mass, muscle, bone. Metabolism 2024;161:156057. PMID: 39481534
32. Takrori E, Peshin S, Singal S. GI Adverse Effects of Anti-Obesity Medications: Systematic Review. Medicina 2025;61(11). PMID: 41303824

Behavioral & Patient-Reported Outcomes

33. Kanu C, Boye KS, Poon JL, et al. Appetite and eating behaviours during retatrutide in T2DM. Diabetes Obes Metab 2025. PMID: 40916752
34. Kanu C, Wu Q, Poon JL, et al. Eating behaviours and weight change: secondary analyses. Diabetes Obes Metab 2025. PMID: 40735804
35. Goetz IA, Kanu C, Hoover A, et al. Perceived benefits of treatment with retatrutide. Obes Pillars 2025. PMID: 41216380
36. Kanu C, Kimel M, Goetz I, et al. Development of the Weight and Emotions Scale (WES). Obes Sci Pract 2026;12(1):e70119. PMID: 41589220

Kidney & Renal

37. Heerspink HJL, Lu Z, Du Y, et al. Effect of Retatrutide on Kidney Parameters in T2DM and/or Obesity. Kidney Int Rep 2025. PMID: 40630318
38. Ma J, Hu X, Zhang W, et al. Comparison of Liraglutide, Tirzepatide, and Retatrutide on DKD in db/db mice. Endocrine 2025. PMID: 39212900

Heart Rate & Cardiovascular Safety

39. Zhang Y, Zhang C, Gong X, et al. GLP-1 RA heart rate effects: systematic review and NMA. Eur J Med Res 2026. PMID: 41582189

Structural Biology & Lipid Mechanism

40. Li W, Zhou Q, Cong Z, et al. Structural insights into triple agonism at GLP-1R, GIPR and GCGR by retatrutide. Cell Discov 2024. PMID: 39019866
41. Wen Y, Lemen D, Lin Y, et al. ANGPTL3/8 reductions following retatrutide parallel lipid reductions. Diabetes Obes Metab 2025. PMID: 40726454

Cancer & Addiction (Preclinical)

42. Cui X, Zhu Y, Zeng L, et al. Retatrutide overcomes obese TNBC therapeutic barrier via HBP/YAP. Adv Sci 2025;12(11):e2407494. PMID: 39868848
43. Marathe SJ, Grey EW, Bohm MS, et al. Retatrutide alleviates obesity-associated cancer progression. NPJ Metab Health Dis 2025. PMID: 40094000
44. Windram et al. Retatrutide attenuates interoceptive effects of alcohol in rats. Psychopharmacology 2025. PMID: 40699363

Sex Differences

45. Yang Y, He L, Han S, et al. Sex Differences in GLP-1 RA Efficacy for Weight Reduction: Systematic Review and Meta-Analysis. J Diabetes 2025. PMID: 40040445
46. Misra S, Narayan RK, Kaur M. Efficacy and safety of retatrutide for obesity: systematic review. J Basic Clin Physiol Pharmacol 2025. PMID: 40728138

Additional Systematic Reviews & Meta-Analyses (2025-2026)

47. Abdrabou Abouelmagd A, et al. Retatrutide for obesity: systematic review and meta-analysis of RCTs. Proc (Bayl Univ Med Cent) 2025. PMID: 40291085
48. Tewari J, Qidwai KA, et al. Retatrutide for obesity management: systematic review and meta-analysis. Expert Rev Clin Pharmacol 2025. PMID: 39817343
49. Moiz A, Filion KB, et al. GLP-1 RAs for Weight Loss in Adults Without Diabetes: Systematic Review. Ann Intern Med 2025. PMID: 39761578
50. Basile C, Merolla A, et al. Incretin-Based Therapies on Blood Pressure: Systematic Review and Meta-Analysis. Eur J Prev Cardiol 2025. PMID: 40899050
51. Wang Y, Zhou Y, et al. GLP-1 Therapies on MASLD/MASH: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2025. PMID: 40489581
52. Zhang S, Yu B, et al. Quantitative Comparison of GLP-1 RAs for Weight Loss: Model-Based Meta-Analysis. Diabetes Technol Ther 2025. PMID: 39911047
53. Liu S, Hu J, et al. Incretin Drugs NMA on Glycemic Control, Weight, and BP. Front Endocrinol 2025. PMID: 39968298
54. Yin Y, Zhang M, et al. GLP-1 RA-Based Therapies on CV Events in Obese Without Diabetes: Meta-Analysis. J Diabetes 2025. PMID: 40207414

Emerging Indications & Psychiatric

55. Hudanich M, Smith SN, et al. GLP-1 RAs on Polycystic Ovarian Syndrome: Scoping Review. Cureus 2025. PMID: 41141001
56. Himmerich H. GLP-1 RAs: A New Pharmacological Treatment for Psychiatric Illnesses? Nervenarzt 2025. PMID: 40042613
57. Himmerich H, Bentley J, McElroy SL. Pharmacological Treatment of Binge Eating Disorder. CNS Drugs 2024. PMID: 39096466

Drug Design & Pharmacology

58. Wang S, Liu Y, et al. Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists. J Med Chem 2025. PMID: 40958513
59. Katsi V, et al. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules 2025. PMID: 40563436

Policy & Supply Chain

60. DiStefano MJ, et al. Compounded GLP-1 RAs: DTC Market in Colorado. J Pharm Policy Pract 2025. PMID: 39776466

MASLD/MASH Reviews

61. Malandris K, et al. Pharmacologic Treatment of MASLD in T2DM. Curr Diab Rep 2026. PMID: 41831086

PRO Instruments

62. Kanu C, Clucas C, et al. Development of Eating Behavior and Appetite Questionnaire (EBAQ). Adv Ther 2026. PMID: 41201783

Clinical Trial Registries

• NCT04881760 — Obesity Phase 2 (completed)
• NCT04867785 — T2DM Phase 2 (completed)
• NCT05931367 — TRIUMPH-4 Knee OA Phase 3 (completed, results Dec 2025)
• NCT06354660 — TRANSCEND-T2D-1 Phase 3 (completed, results Mar 2026)
• NCT06662383 — TRIUMPH-5 vs Tirzepatide Phase 3 (active, results expected Dec 2026)
• NCT06260722 — TRANSCEND-T2D-2 vs Semaglutide Phase 3 (active, completion Jan 2027)
• NCT06383390 — TRIUMPH-Outcomes ASCVD+CKD (active, N=10,000)
• NCT07165028 — SYNERGY-Outcomes Reta+Tirz for MASH (recruiting, N=4,500)
• NCT06859268 — Weight Maintenance Phase 3 (active)
• NCT07035093 — Chronic Low Back Pain Phase 3 (recruiting)
• NCT07232719 — Obesity Phase 3 (recruiting, N=250, Lilly)
• NCT07357415 — Dose Escalation Schemes Phase 3 (recruiting, N=600, Lilly)
• NCT07467447 — Maintenance Dosing Phase 2 (recruiting, N=300, Hudson Biotech — first non-Lilly trial)
• NCT05929079 — TRIUMPH OSA subset Phase 3 (active, N=1,000)
• NCT06808802 — DDI Metoprolol Phase 1 (completed)
• NCT05916560 — Hepatic Impairment PK Phase 1 (completed)
• NCT05611957 — Renal Impairment PK Phase 1 (completed)
• NCT06313528 — Energy Metabolism Phase 1 (completed)
• NCT06039826 — DDI Oral Contraceptive Phase 1 (completed)
• Full pipeline: 47 registered trials. See Clinical Trials table in Deep Dive section.
• Eli Lilly pipeline: https://www.lilly.com/discovery/pipeline

Total references cited: 62 peer-reviewed + 20 trial registries